Systane^® PRO
‡ 47% of patients experience meaningful symptom relief at 12 hours, N=153.
† Not a rewetting solution.
‡ In vitro data. Based on Systane^® ORIGINAL.
§ In vitro data. Based on Systane^® COMPLETE.

1. Alcon data on file 2025.
2. Kesavan S, Prud'homme RK. Rheology of guar and (hydroxypropyl) guar crosslinked by borate. Macromolecules. 1992;25(7).
3. Ubels JL, et al. Pre-clinical investigation of the efficacy of an artificial tear solution containing hydroxypropyl-guar as a gelling agent. Curr Eyes Res. 2004;28(6).
4. Rangarajan R, et al. Effects of a hyaluronic acid/hydroxypropyl guar artificial tear solution on protection, recovery, and lubricity in models of corneal epithelium. J Ocul Pharmacol Ther. 2015;31(8).
5. Rangarajan R, Ketelson H. Preclinical evaluation of a new hydroxypropyl-guar phospholipid nanoemulsion-based artificial tear formulation in models of corneal epithelium. J Ocul Pharmacol Ther. 2019;35(1):32-37.

© 2024 Alcon Inc. CA-SAF-2600120